Cargando…
Contemporary Management of Localized Resectable Pancreatic Cancer
Pancreatic cancer is the third most common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15–20% of patients at the time of initial diagnosis. Accumulating evidence sugge...
Autores principales: | Kommalapati, Anuhya, Tella, Sri Harsha, Goyal, Gaurav, Ma, Wen Wee, Mahipal, Amit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789374/ https://www.ncbi.nlm.nih.gov/pubmed/29361690 http://dx.doi.org/10.3390/cancers10010024 |
Ejemplares similares
-
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
por: Kommalapati, Anuhya, et al.
Publicado: (2021) -
Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019) -
First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
por: Tella, Sri Harsha, et al.
Publicado: (2022) -
Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
por: Mahipal, Amit, et al.
Publicado: (2019) -
Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations
por: Storandt, Michael H, et al.
Publicado: (2022)